Prolia (Denosumab) Side Effects: Potentially Permanent Adverse Events Explained

What Is Denosumab and How Does It Work?

Denosumab binds with high affinity to RANK ligand (RANKL), a protein that drives the formation, function, and survival of osteoclasts. By blocking this signal, the drug substantially reduces bone resorption. The FDA approved Prolia in June 2010 for postmenopausal women at high fracture risk, and the label has since expanded to include men with osteoporosis and patients on long-term glucocorticoid therapy [1].

Efficacy Context

The FREEDOM trial (N=7,808) showed denosumab 60 mg every 6 months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months compared with placebo [2]. These are meaningful reductions, but they come with a risk profile that every prescriber must communicate clearly.

Why the Mechanism Matters for Side Effects

Because denosumab suppresses osteoclast activity so completely, it can impair bone remodeling in ways that are not fully reversible when the drug is stopped. The effects on bone turnover markers normalize within 12 months of the last injection, but some structural consequences, particularly ONJ and rebound fracture risk, may persist far longer [3].

Osteonecrosis of the Jaw (ONJ): A Potentially Permanent Complication

ONJ is defined as exposed bone in the maxillofacial region that does not heal within eight weeks after identification by a healthcare provider. Once established, ONJ can become a chronic, disfiguring condition that significantly impairs eating, speaking, and quality of life. Full resolution is not guaranteed even with prolonged conservative management.

Incidence Data

In the FREEDOM trial and its extension (up to 10 years of exposure), ONJ occurred in 13 of 4,550 denosumab-treated patients (0.3%) at the osteoporosis dose [2]. Rates are substantially higher in oncology patients receiving denosumab 120 mg monthly (Xgeva), with estimates ranging from 1% to 2% per year of exposure [4]. The FDA label for Prolia carries a specific warning for ONJ, stating that patients should have a dental examination before initiating therapy and should avoid invasive dental procedures during treatment [1].

Risk Factors for ONJ

Patients at highest risk include those with poor oral hygiene, active dental disease, prior tooth extraction or jaw surgery, concomitant corticosteroid use, anemia, or a history of bisphosphonate treatment. Cancer patients receiving chemotherapy face additional risk. A 2018 systematic review in the Journal of Dental Research identified prior dental extraction as the single strongest modifiable risk factor [5].

Managing ONJ Risk

The American Association of Oral and Maxillofacial Surgeons recommends completing all elective invasive dental work before starting any antiresorptive therapy [5]. Once ONJ develops, standard care includes antibacterial mouthwash (chlorhexidine 0.12%), conservative surgical debridement only when tissue is necrotic, and antibiotic therapy for superinfection. Recovery can take months to years, and a subset of patients never achieve full mucosal coverage of the exposed bone [4].

Atypical Femur Fractures: Stress Fractures That May Require Surgery

Atypical femur fractures (AFFs) are low-energy transverse or short oblique fractures of the subtrochanteric or diaphyseal femur. They differ from standard osteoporotic fractures because they occur in cortical (not cancellous) bone and often present with prodromal thigh or groin pain weeks to months before complete fracture [6].

How Common Are AFFs With Denosumab?

The American Society for Bone and Mineral Research (ASBMR) task force estimated AFF incidence at approximately 3.2 to 50 cases per 100,000 person-years with antiresorptive therapy, rising substantially with duration of treatment beyond five years [6]. In an analysis of the FREEDOM extension cohort published in the Journal of Bone and Mineral Research, longer cumulative denosumab exposure correlated with higher AFF rates [7]. The FDA label includes a specific warning for AFFs under the section on "Warnings and Precautions" [1].

Why AFFs Can Become Permanent

AFFs heal poorly. Because denosumab suppresses osteoclast-driven bone remodeling, the micro-damage accumulation that precedes AFF may not be repaired efficiently. Surgical fixation with an intramedullary nail is the standard treatment, but delayed union and non-union occur in a meaningful proportion of cases [6]. Patients who develop an AFF in one femur face an approximately 28% risk of a contralateral AFF within two years, according to a 2014 cohort study [6].

Prodromal Pain: An Actionable Warning Sign

Any patient on long-term denosumab who reports new thigh or groin pain should have bilateral femur X-rays immediately. If the fracture is incomplete (a "dreaded black line" of cortical stress visible on imaging), orthopedic consultation is appropriate. Stopping denosumab and switching to teriparatide (PTH analog) has been used to promote AFF healing, though evidence remains limited to case series [7].

Severe Hypocalcemia: Life-Threatening and Potentially Prolonged

Denosumab lowers serum calcium because it so effectively reduces osteoclast activity and bone resorption, the source of calcium release into the bloodstream. Most hypocalcemia is mild and asymptomatic, but severe cases can cause tetany, seizures, prolonged QT interval, and cardiac arrhythmias [8].

Who Is at Highest Risk?

Patients with chronic kidney disease (CKD) stages 3 to 5, hypoparathyroidism, malabsorption syndromes, or vitamin D deficiency face the greatest risk. The FDA label states that Prolia is contraindicated in patients with pre-existing hypocalcemia until the condition is corrected [1]. A 2018 pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) found that 46% of serious hypocalcemia events occurred within the first 30 days after the initial Prolia injection [8].

Monitoring and Prevention Protocol

Serum calcium, phosphorus, magnesium, and 25-hydroxyvitamin D should be measured before every injection. All patients should receive adequate calcium (1,000 to 1,200 mg/day in divided doses) and vitamin D (at least 800 IU/day) as co-therapy; patients with CKD may need calcitriol rather than standard vitamin D [1]. If symptomatic hypocalcemia develops, intravenous calcium gluconate is first-line treatment in hospital settings.

Rebound Vertebral Fractures After Discontinuation: A Distinct and Serious Risk

This is perhaps the least understood and most under-communicated risk of Prolia. When denosumab is stopped, osteoclast activity rebounds dramatically above pretreatment levels within three to six months. Bone mineral density (BMD) returns rapidly toward baseline, and bone turnover markers overshoot normal ranges. The clinical result can be multiple vertebral fractures occurring in rapid succession, even in patients who experienced no fractures while on therapy [9].

Incidence of Rebound Fractures

A 2017 study in Osteoporosis International (N=1,001 women who discontinued denosumab) reported that 7.1% of those who stopped without transitioning to an alternative antiresorptive experienced at least one new vertebral fracture within 12 months [9]. A case series published in the Journal of Clinical Endocrinology and Metabolism described patients sustaining three to seven new vertebral fractures within months of stopping denosumab, some leading to permanent height loss, kyphotic deformity, and chronic pain [10].

Why This Qualifies as a Potentially Permanent Effect

The vertebral fractures themselves heal, but the resulting deformity, chronic back pain, loss of height, and reduced lung capacity from thoracic compression may be permanent. Patients who sustain multiple rebound vertebral fractures have been reported to lose four to six centimeters of height in a matter of months, a change that cannot be fully reversed [10].

The Transition Protocol: How to Stop Denosumab Safely

The Endocrine Society and major osteoporosis guidelines now state that denosumab should not be stopped without a transition plan. The most evidence-supported approach is:

1. Administer a bisphosphonate (most commonly zoledronic acid 5 mg IV) approximately six months after the last Prolia injection, timed to when bone turnover markers begin to rise.
2. Measure bone turnover markers (serum CTX or P1NP) at six and twelve months after the final Prolia dose to confirm the bisphosphonate is suppressing the rebound.
3. Consider sequential denosumab dosing rather than abrupt discontinuation in patients at very high fracture risk.

A 2020 randomized controlled trial published in the Journal of Bone and Mineral Research (N=61) confirmed that a single infusion of zoledronic acid six months after the last denosumab dose maintained BMD at 12 and 24 months, compared with significant BMD loss in untreated controls [11].

Immunosuppression and Serious Infections

Denosumab suppresses RANKL, which is also expressed on immune cells. The FDA label lists serious infections, including skin infections (primarily cellulitis leading to hospitalization), endocarditis, and urinary tract infections, as identified risks [1]. In the FREEDOM trial, serious infections occurred in 4.1% of denosumab patients versus 3.4% of placebo patients, a difference that reached statistical significance in the extension phase [2].

Skin Infections (Cellulitis)

Cellulitis and other dermatologic infections were the most frequently reported serious infection in clinical trials. Patients should be counseled to seek prompt evaluation for any expanding skin redness, warmth, or swelling. Delayed treatment of cellulitis can result in necrotizing fasciitis, osteomyelitis, or sepsis, all of which carry permanent sequelae.

Endocarditis

A 2019 case-control study published in JAMA Internal Medicine identified a statistically significant association between denosumab use and endocarditis (adjusted odds ratio 2.24, 95% CI 1.04 to 4.81) [12]. Endocarditis can permanently damage heart valves and may require surgical replacement.

Hypersensitivity Reactions and Dermatologic Events

Rare but serious hypersensitivity reactions, including anaphylaxis, have been reported with Prolia. The FDA label includes a warning that patients experiencing symptoms of anaphylaxis (urticaria, facial edema, lip swelling, dyspnea, or hypotension) should not receive further injections [1]. Dermatitis, eczema, and rashes are more common and generally resolve, but persistent eczematous reactions have been documented in post-marketing reports submitted to FAERS [8].

Long-Term Suppression of Bone Turnover

Prolonged suppression of bone remodeling is a shared concern for all potent antiresorptive agents. Bone accumulates micro-cracks over time that are normally repaired through remodeling cycles. When remodeling is suppressed for years, these micro-cracks accumulate, and bone may paradoxically become more brittle in some sites despite higher measured BMD [7].

What the Long-Term Extension Data Show

The FREEDOM extension followed patients receiving continuous denosumab for up to 10 years. Fracture rates remained low during this extended period, and no new safety signals emerged regarding over-suppression at the osteoporosis dose of 60 mg every six months [2]. The Endocrine Society's 2019 clinical practice guideline states: "For patients who have been treated for 5 to 10 years with denosumab, ongoing therapy is appropriate for those at high fracture risk, given the loss of benefit on stopping treatment." [13].

Special Populations: Pregnancy, Renal Impairment, and Pediatric Patients

Denosumab is classified as FDA Pregnancy Category X equivalent under current labeling; animal studies showed fetal harm at doses lower than the human therapeutic dose, and the drug is contraindicated during pregnancy [1]. Women of childbearing potential must use effective contraception during therapy and for at least five months after the final dose.

Patients with severe renal impairment (creatinine clearance <30 mL/min) or on dialysis face the highest hypocalcemia risk and require more frequent serum calcium monitoring, often weekly for the first month after each dose [1].

Prolia is not approved for use in pediatric patients, and the FDA label explicitly states that it may impair epiphyseal growth plate development, a potentially permanent effect in growing bone [1].

Practical Checklist Before Starting or Stopping Prolia

Before initiating denosumab, a clinician should confirm:

• Serum calcium is within normal limits
• 25-hydroxyvitamin D is at least 30 ng/mL
• A dental examination has been completed within the prior 12 months
• Renal function (eGFR) has been measured
• The patient is not pregnant and is using contraception if of childbearing potential
• A documented discontinuation plan exists if the drug is started

Before stopping denosumab, the clinician should:

• Plan a bisphosphonate transition (zoledronic acid 5 mg IV at six months after the last injection, or oral alendronate 70 mg weekly starting at the six-month mark)
• Measure bone turnover markers at 6 and 12 months post-discontinuation
• Inform the patient explicitly about rebound fracture risk and the importance of follow-through

Patients who stop Prolia without a transition plan and are then lost to follow-up represent the highest-risk group for rebound vertebral fractures. The FDA-approved label itself states that "discontinuation of Prolia therapy should be considered only after discussing the risks and benefits with patients." [1]